Management, Pipeline Make Tesaro (TSRO) an Attractive Speculative Play - Cramer

November 12, 2012 9:55 AM EST Send to a Friend
Get Alerts TSRO Hot Sheet
Price: $26.08 --0%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 11 | New: 14
Trade TSRO Now!
Join SI Premium – FREE
Tesaro (Nasdaq: TSRO) shares are higher amid a positive mention by famed stock picker Jim Cramer late last week.

According to Cramer, Tesaro has become his favorite speculative biotech stock. Though the company hasn't been public very long, Cramer noted the strong management behind the firm, folks with a history of building and selling companies.

Tesaro focuses primarily on improving the lives of cancer patients. It's first dug -- Rolapitant -- was licensed from Opko Health (NYSE: OPK) for a grat price and the drug is now in Phase III testing. Rolapitant helps to prevent chemo patients from experiencing nausea during treatment.

Two other drugs Tesaro currently has in development include one that attacks tumors directly and the other aiming to treat specific lung cancers.

Cramer notes that Tesaro has about $138 million in cash with no debt on the books. Those sort of numbers and its robust pipeline make Tesaro a stock that could easily trade for well above its current range.

Shares are up 5.6 percent on the session and up about 18 percent from its IPO price of $13.50.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Insiders' Blog

Related Entities

Jim Cramer

Add Your Comment